Skip to main content

Advertisement

Table 6 Effects of subgroups on late toxicity in nasopharyngeal carcinoma underwent CV-IMRT versus RV-IMRT

From: Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study

Variate P value
Xerostomia Mucositis Skin reaction Dysphagia Hearing loss Blurred vision
Sex Female 0.511 0.562 0.362 0.36 0.077 0.625
Male 0.038 0.145 0.893 0.716 0.042 0.532
Age < 45 0.483 0.831 0.613 0.32 0.023 0.327
≥45 0.036 0.384 0.215 0.838 0.12 0.756
T stage T1–2 0.008 0.348 0.987 0.97 0.01 0.06
T3–4 0.995 0.717 0.542 0.252 0.253 0.272
N stage N0–1 0.255 0.546 0.676 0.787 0.01 0.969
N2–3 0.079 0.553 0.81 0.236 0.185 0.252
Clinical stage I-II 0.269 0.373 0.78 1 0.011 0.607
III-IV 0.087 0.635 0.765 0.353 0.099 0.779
Neoadjuvant/adjuvant chemotherapy No 0.715 0.897 0.363 0.675 0.017 1
Yes 0.036 0.406 0.86 0.318 0.049 0.585
Concurrent chemotherapy No 0.419 0.605 0.402 0.696 0.003
Yes 0.053 0.492 0.831 0.318 0.069 0.412
  1. CV-IMRT conventional-volume intensity-modulated radiation therapy, RV-IMRT reduced-volume intensity-modulated radiation therapy